Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. There are currently few available therapies to treat and prevent the severe consequences of this disease, which affects as much as 10 percent of the world's population.
The company has two major programs; its lead program targets acute kidney injury (AKI). AKI is the sudden loss of kidney function that afflicts more than 1.2 million people each year in the United States and can lead to kidney failure and dialysis. The company's second program addresses diabetic nephropathy—a leading cause of chronic kidney disease (CKD) that can result in permanent loss of kidney function and the need for dialysis.
|06•18•14||Thrasos Appoints Donald Notman as Senior Vice President and Chief Financial Officer more >|
|06•03•14||Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury more >|
|02•04•14||FDA Grants Thrasos Fast Track Designation for THR-184 in Acute Kidney Injury more >|